Comorbidities and side effects of the imunomodulatory treatment in multiple sclerosis

Abstract

Multiple sclerosis is a demyelinating, neurodegenerative disease of the central nervous system, that affects the young adult and is associated with a high degree of disability. Physical and mental comorbidity and adverse health behaviors are common in patients with MS. Comorbidities and health behaviors are associated with adverse outcomes in MS and should be considered in the assessment and management of patients with MS. We have studied a group of 150 MS patients treated with immunomodulators inside the Romanian national MS treatment programme. The patients we analysed corresponded to the available literature in matters or number, age and sex. We searched for associated pathology and side effects of the treatment. After selecting and statistically analyzing the data we concluded that dyslipidemia was the most common comorbidity, followed by hyperglicemia and vertebral hernia. The presence or not of a comorbidity before the treatment does not relate to the EDSS score (p